Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Chin Med J (Engl). 2011 May;124(9):1409-21.
To summarize the risk stratification and current treatment strategies for acute myeloid leukemia (AML) and discuss the role of emerging novel agents that might be applied in future clinical trials.
The data in this article were collected from PubMed database with relevant English articles published from 1991 to 2009.
Articles regarding the risk stratification and therapeutic options of AML, as well as the characteristics of leukemic stem cells were selected.
AML is a heterogeneous disease with variable clinical outcome dependent on several prognostic factors, including age, cytogenetics and molecular markers. The advances in the understanding of AML pathogenesis and development will generate potential novel agents that might improve the treatment results of standard chemotherapy.
Deeper insight into the multiple transforming events of AML may aid us in designing combinations of small molecule inhibitors based on the individual patient characteristics.
总结急性髓系白血病（AML）的风险分层和当前治疗策略，并探讨可能应用于未来临床试验的新兴新型药物的作用。
本文数据来源于 PubMed 数据库，检索了 1991 年至 2009 年发表的相关英文文献。
选择了关于 AML 的风险分层和治疗选择以及白血病干细胞特征的文章。
AML 是一种异质性疾病，其临床结果因多种预后因素而异，包括年龄、细胞遗传学和分子标志物。对 AML 发病机制和发展的深入了解将产生潜在的新型药物，可能改善标准化疗的治疗效果。
深入了解 AML 的多种转化事件可能有助于我们根据个体患者特征设计基于小分子抑制剂的组合。
